FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079062174> ?p ?o ?g. }

• W2079062174 endingPage "1462" @default.
• W2079062174 startingPage "1458" @default.
• W2079062174 abstract "Disseminated fungal infection is a major cause of morbidity and mortality in children undergoing hematopoietic stem cell transplantation (HSCT). Prophylaxis with amphotericin B can be limited by renal toxicity. Oral triazoles can be limited by poor absorption, large interindividual pharmacokinetic (PK) variability, and hepatic toxicity, leading to interruptions in therapy and breakthrough infections. Intravenous (i.v.) micafungin has potential advantages, because of its better safety profile, specifically in terms of hepatic and renal toxicity, and lack of drug-drug interactions with common medications used in the HSCT setting. We hypothesized that higher dose micafungin (3 mg/kg) every other day will provide drug exposure similar to standard dosing (1 mg/kg) given daily, and improve patient compliance in very young children in whom oral medications can be challenging, at reduced administration costs. Both animal and adult patient data support the use of this approach. Fifteen children (M/F = 11/4, aged ≤10 years; mean: 3.9 years, range: 0.6-10 years) with various hematologic, metabolic, and immune deficiency disorders undergoing HSCT received a single dose of micafungin (3 mg/kg) i.v. over 1 hour. Dose selection was based on published PK data in pediatric patients, and exploration of different dosing regimens using Monte Carlo PK/PD simulation. Blood samples were drawn around this dose and PK analysis was conducted using standard noncompartmental methods. Micafungin at 3 mg/kg dose was well tolerated in all patients. Measurable plasma concentrations were present in all cases at 48 hours. Half-life and clearance observed were comparable to previous pediatric PK data, with clearance being higher than adults as expected. Volume of distribution was higher in our patients compared to published pediatric data, likely because of a larger proportion of very young children in our study cohort. After correction for protein binding, concentrations at the end of the dosing interval during maintenance treatment remain above the minimum inhibitory concentration (MIC) of highly susceptible fungal pathogens. These data suggest that alternate day micafungin dosing, as described here, may provide an attractive alternative for antifungal prophylaxis in HSCT patients and merits further evaluation. Disseminated fungal infection is a major cause of morbidity and mortality in children undergoing hematopoietic stem cell transplantation (HSCT). Prophylaxis with amphotericin B can be limited by renal toxicity. Oral triazoles can be limited by poor absorption, large interindividual pharmacokinetic (PK) variability, and hepatic toxicity, leading to interruptions in therapy and breakthrough infections. Intravenous (i.v.) micafungin has potential advantages, because of its better safety profile, specifically in terms of hepatic and renal toxicity, and lack of drug-drug interactions with common medications used in the HSCT setting. We hypothesized that higher dose micafungin (3 mg/kg) every other day will provide drug exposure similar to standard dosing (1 mg/kg) given daily, and improve patient compliance in very young children in whom oral medications can be challenging, at reduced administration costs. Both animal and adult patient data support the use of this approach. Fifteen children (M/F = 11/4, aged ≤10 years; mean: 3.9 years, range: 0.6-10 years) with various hematologic, metabolic, and immune deficiency disorders undergoing HSCT received a single dose of micafungin (3 mg/kg) i.v. over 1 hour. Dose selection was based on published PK data in pediatric patients, and exploration of different dosing regimens using Monte Carlo PK/PD simulation. Blood samples were drawn around this dose and PK analysis was conducted using standard noncompartmental methods. Micafungin at 3 mg/kg dose was well tolerated in all patients. Measurable plasma concentrations were present in all cases at 48 hours. Half-life and clearance observed were comparable to previous pediatric PK data, with clearance being higher than adults as expected. Volume of distribution was higher in our patients compared to published pediatric data, likely because of a larger proportion of very young children in our study cohort. After correction for protein binding, concentrations at the end of the dosing interval during maintenance treatment remain above the minimum inhibitory concentration (MIC) of highly susceptible fungal pathogens. These data suggest that alternate day micafungin dosing, as described here, may provide an attractive alternative for antifungal prophylaxis in HSCT patients and merits further evaluation." @default.
• W2079062174 created "2016-06-24" @default.
• W2079062174 creator A5011397007 @default.
• W2079062174 creator A5011524144 @default.
• W2079062174 creator A5028145044 @default.
• W2079062174 creator A5029451403 @default.
• W2079062174 creator A5034545991 @default.
• W2079062174 creator A5040060343 @default.
• W2079062174 creator A5041492552 @default.
• W2079062174 creator A5048379987 @default.
• W2079062174 creator A5063472080 @default.
• W2079062174 creator A5068698149 @default.
• W2079062174 creator A5072140211 @default.
• W2079062174 creator A5085671725 @default.
• W2079062174 date "2010-10-01" @default.
• W2079062174 modified "2023-09-26" @default.
• W2079062174 title "Alternate-Day Micafungin Antifungal Prophylaxis in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Pharmacokinetic Study" @default.
• W2079062174 cites W1977651093 @default.
• W2079062174 cites W2024387621 @default.
• W2079062174 cites W2027460001 @default.
• W2079062174 cites W2033991528 @default.
• W2079062174 cites W2036348455 @default.
• W2079062174 cites W2040198427 @default.
• W2079062174 cites W2046891447 @default.
• W2079062174 cites W2054495423 @default.
• W2079062174 cites W2087349592 @default.
• W2079062174 cites W2090314830 @default.
• W2079062174 cites W2095580652 @default.
• W2079062174 cites W2098017193 @default.
• W2079062174 cites W2098490735 @default.
• W2079062174 cites W2100967944 @default.
• W2079062174 cites W2119259239 @default.
• W2079062174 cites W2121281525 @default.
• W2079062174 cites W2123787514 @default.
• W2079062174 cites W2134541747 @default.
• W2079062174 cites W2138620668 @default.
• W2079062174 cites W2142418809 @default.
• W2079062174 cites W2151085150 @default.
• W2079062174 cites W2152151290 @default.
• W2079062174 cites W2158070953 @default.
• W2079062174 cites W2158530375 @default.
• W2079062174 cites W2163769057 @default.
• W2079062174 cites W2171516933 @default.
• W2079062174 cites W84273483 @default.
• W2079062174 doi "https://doi.org/10.1016/j.bbmt.2010.05.002" @default.
• W2079062174 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20546908" @default.
• W2079062174 hasPublicationYear "2010" @default.
• W2079062174 type Work @default.
• W2079062174 sameAs 2079062174 @default.
• W2079062174 citedByCount "41" @default.
• W2079062174 countsByYear W20790621742012 @default.
• W2079062174 countsByYear W20790621742014 @default.
• W2079062174 countsByYear W20790621742015 @default.
• W2079062174 countsByYear W20790621742016 @default.
• W2079062174 countsByYear W20790621742017 @default.
• W2079062174 countsByYear W20790621742018 @default.
• W2079062174 countsByYear W20790621742019 @default.
• W2079062174 countsByYear W20790621742020 @default.
• W2079062174 countsByYear W20790621742021 @default.
• W2079062174 crossrefType "journal-article" @default.
• W2079062174 hasAuthorship W2079062174A5011397007 @default.
• W2079062174 hasAuthorship W2079062174A5011524144 @default.
• W2079062174 hasAuthorship W2079062174A5028145044 @default.
• W2079062174 hasAuthorship W2079062174A5029451403 @default.
• W2079062174 hasAuthorship W2079062174A5034545991 @default.
• W2079062174 hasAuthorship W2079062174A5040060343 @default.
• W2079062174 hasAuthorship W2079062174A5041492552 @default.
• W2079062174 hasAuthorship W2079062174A5048379987 @default.
• W2079062174 hasAuthorship W2079062174A5063472080 @default.
• W2079062174 hasAuthorship W2079062174A5068698149 @default.
• W2079062174 hasAuthorship W2079062174A5072140211 @default.
• W2079062174 hasAuthorship W2079062174A5085671725 @default.
• W2079062174 hasBestOaLocation W20790621741 @default.
• W2079062174 hasConcept C112705442 @default.
• W2079062174 hasConcept C126322002 @default.
• W2079062174 hasConcept C16005928 @default.
• W2079062174 hasConcept C2777288759 @default.
• W2079062174 hasConcept C2777408962 @default.
• W2079062174 hasConcept C2779020398 @default.
• W2079062174 hasConcept C2779548794 @default.
• W2079062174 hasConcept C2779629538 @default.
• W2079062174 hasConcept C2911091166 @default.
• W2079062174 hasConcept C29730261 @default.
• W2079062174 hasConcept C71924100 @default.
• W2079062174 hasConcept C98274493 @default.
• W2079062174 hasConceptScore W2079062174C112705442 @default.
• W2079062174 hasConceptScore W2079062174C126322002 @default.
• W2079062174 hasConceptScore W2079062174C16005928 @default.
• W2079062174 hasConceptScore W2079062174C2777288759 @default.
• W2079062174 hasConceptScore W2079062174C2777408962 @default.
• W2079062174 hasConceptScore W2079062174C2779020398 @default.
• W2079062174 hasConceptScore W2079062174C2779548794 @default.
• W2079062174 hasConceptScore W2079062174C2779629538 @default.
• W2079062174 hasConceptScore W2079062174C2911091166 @default.
• W2079062174 hasConceptScore W2079062174C29730261 @default.
• W2079062174 hasConceptScore W2079062174C71924100 @default.
• W2079062174 hasConceptScore W2079062174C98274493 @default.
• W2079062174 hasIssue "10" @default.

• next